Rutin, a Quercetin Glycoside
Rutin, a natural flavonoid glycoside found in many plants like buckwheat, citrus fruits, and apples, has shown promising neuroprotective and anticancer properties.
Rutin is a flavonoid glycoside composed of quercetin bound to the disaccharide rutinose. It is widely found in buckwheat, citrus fruits, apples, and tea. In cancer models, rutin exhibits antioxidant, anti-inflammatory, anti-proliferative, and pro-apoptotic effects. Because it is glycosylated, rutin itself has relatively low cellular permeability; many biological effects are mediated after intestinal hydrolysis to quercetin and subsequent phase-II metabolites. Mechanistically, rutin is most consistently associated with suppression of NF-κB and PI3K/AKT signaling, modulation of MAPK pathways, redox regulation (Nrf2/ROS balance), inhibition of angiogenesis (VEGF), and induction of cell-cycle arrest and apoptosis in preclinical systems. Effects are model-dependent and often concentration-dependent, with antioxidant behavior dominating in normal tissue contexts and context-dependent pro-oxidant effects described in some tumor settings.
-Scavenges free radicals, reduces oxidative stress
-Inhibits pro-inflammatory cytokines like IL-1β, TNF-α, and reduces activation of NF-κB.
-Inhibition of Aβ Aggregation (AD)
-Mild inhibitory effects on acetylcholinesterase (AChE), helping enhance cholinergic function.
-May upregulate BDNF expression
Cancer:
-Induces cell cycle arrest in G2/M phase.
-Inhibits VEGF, Suppresses MMP-2 and MMP-9
-Inhibits PI3K/Akt/mTOR, MAPK, and NF-κB signaling pathways.
-Enhances sensitivity to Chemotherapy drugs like doxorubicin and cisplatin
Rutin has poor oral bioavailability, but this can be improved with nanoformulations or co-administration with absorption enhancers like piperine or quercetin.
Cancer Pathway Table: Rutin
| Rank |
Pathway / Axis |
Cancer / Tumor Context |
Normal Tissue Context |
TSF |
Primary Effect |
Notes / Interpretation |
| 1 |
NF-κB inflammatory / survival signaling |
NF-κB ↓; COX-2, cytokines ↓ (reported) |
Inflammatory tone ↓ |
R, G |
Anti-inflammatory / anti-survival |
Frequently reported mechanism; contributes to reduced tumor-promoting inflammation and survival signaling. |
| 2 |
PI3K → AKT → mTOR axis |
PI3K/AKT ↓; proliferation ↓ (model-dependent) |
↔ |
R, G |
Growth signaling suppression |
Observed in several tumor models; often secondary to upstream redox and inflammatory modulation. |
| 3 |
Cell-cycle regulation (Cyclins/CDKs; G1 or G2/M arrest) |
Cell-cycle arrest ↑ (reported) |
↔ |
G |
Cytostasis |
Associated with reduced Cyclin D1/CDK expression; typically downstream of survival pathway inhibition. |
| 4 |
Intrinsic apoptosis (mitochondrial pathway) |
Bax ↑; Bcl-2 ↓; caspases ↑ (reported) |
Minimal activation at lower exposure |
G |
Apoptotic execution |
Apoptosis induction frequently reported in vitro; magnitude depends on achievable intracellular concentration. |
| 5 |
ROS modulation (biphasic redox behavior) |
ROS ↑ in some tumor contexts; apoptosis ↑ |
ROS ↓ (antioxidant protection) |
P, R |
Redox modulation |
Rutin is classically antioxidant but may promote oxidative stress in tumor cells under certain conditions (dose/metal-dependent). |
| 6 |
Nrf2 / ARE antioxidant response |
Context-dependent modulation |
Nrf2 ↑; antioxidant enzymes ↑ |
R, G |
Redox buffering |
Common polyphenol signature; may protect normal tissue from oxidative injury. |
| 7 |
MAPK pathways (ERK / JNK / p38) |
Stress-MAPK modulation (context-dependent) |
↔ |
P, R, G |
Signal reprogramming |
JNK/p38 activation reported in apoptosis contexts; ERK modulation varies by model. |
| 8 |
Angiogenesis signaling (VEGF) |
VEGF ↓; angiogenic outputs ↓ (reported) |
↔ |
G |
Anti-angiogenic support |
Often secondary to NF-κB and PI3K suppression. |
| 9 |
Invasion / metastasis (MMPs / EMT) |
MMP2/MMP9 ↓; migration ↓ (reported) |
↔ |
G |
Anti-invasive phenotype |
Typically downstream of inflammatory and MAPK modulation. |
| 10 |
Bioavailability constraint (glycoside → quercetin metabolism) |
Systemic exposure mainly as metabolites |
— |
— |
Translation constraint |
Rutin has limited direct cellular uptake; many effects likely mediated after conversion to quercetin and phase-II metabolites. |
TSF: P = 0–30 min (rapid redox interactions), R = 30 min–3 hr (acute signaling shifts), G = >3 hr (gene-regulatory adaptation and phenotype outcomes).
Alzheimer’s Disease (AD) Summary — Rutin
Rutin has been studied in preclinical neurodegeneration models for its antioxidant, anti-inflammatory, and mitochondrial-protective properties. It is reported to modulate Nrf2 signaling, suppress NF-κB–mediated neuroinflammation, reduce oxidative stress, and attenuate amyloid-β–induced neuronal injury in experimental systems. Many effects may be mediated after hydrolysis to quercetin. Human clinical evidence remains limited.
Alzheimer’s Disease Table: Rutin
| Rank |
Pathway / Axis |
AD / Neurodegeneration Context |
Normal Brain Context |
TSF |
Primary Effect |
Notes / Interpretation |
| 1 |
Nrf2 / ARE antioxidant response |
Nrf2 ↑; HO-1 ↑; GSH ↑; oxidative damage ↓ (reported) |
Redox homeostasis support |
R, G |
Antioxidant neuroprotection |
Consistent polyphenol signature; reduces lipid peroxidation and ROS markers in AD models. |
| 2 |
NF-κB / neuroinflammation |
Microglial activation ↓; TNF-α / IL-1β ↓ (reported) |
Inflammatory tone moderation |
R, G |
Anti-inflammatory modulation |
Neuroinflammation is a core AD driver; rutin shows suppression in animal models. |
| 3 |
Amyloid-β toxicity modulation |
Aβ-induced ROS ↓; neuronal apoptosis ↓ (reported) |
↔ |
G |
Anti-amyloid support |
Evidence mainly from in vitro and rodent models; not confirmed clinically. |
| 4 |
Mitochondrial protection |
ΔΨm stabilization; ATP preservation (reported) |
Mitochondrial resilience |
R |
Bioenergetic protection |
Opposes mitochondrial dysfunction induced by oxidative stress. |
| 5 |
MAPK (JNK / p38 stress signaling) |
Stress-MAPK suppression (reported) |
↔ |
P, R |
Stress signaling reduction |
JNK/p38 activation linked to neuronal apoptosis; suppression reported in models. |
| 6 |
Cholinergic signaling (reported in some models) |
AChE activity ↓ (reported) |
↔ |
G |
Cognitive support (model-based) |
Evidence limited; magnitude smaller than pharmaceutical AChE inhibitors. |
| 7 |
BBB penetration (metabolite-driven) |
Effects likely via quercetin metabolites |
Systemic metabolism required |
— |
Translation constraint |
Parent rutin has limited direct brain penetration; hydrolysis/metabolism important. |
| 8 |
Clinical evidence |
Limited human AD trials |
— |
— |
Evidence constraint |
Most data preclinical; not established as AD therapy. |
TSF: P = 0–30 min (early signaling modulation), R = 30 min–3 hr (stress-response shifts), G = >3 hr (gene-regulatory and neuroprotective outcomes).
|